Apellis Pharmaceuticals, Inc. Ratios

Ratios Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 99.70%92.53%85.25%84.93%
EBT Margin 13,572.80%5,073.70%5,765.51%-136.86%-1,120.75%-863.81%-132.76%-25.18%
EBIT Margin 13,546.94%5,090.53%5,449.67%-85.27%-805.67%-788.38%-130.39%-21.11%
EBITDA Margin 13,610.74%5,078.59%5,766.09%-137.58%-1,124.24%-863.09%-133.97%-25.29%
Operating Margin 13,546.94%5,090.53%5,449.67%-85.27%-805.67%-788.38%-130.39%-21.11%
Net Margin 13,572.80%5,073.70%5,765.51%-137.59%-1,121.27%-864.70%-133.29%-25.32%
FCF Margin 12,433.68%5,222.48%4,027.02%-66.19%-847.66%-683.18%-150.16%-11.30%
Efficiency
Inventory Average 51.00M116.04M113.88M
Assets Average 921.17M820.99M774.47M836.89M
Equity Average 201.61M184.27M182.20M211.53M
Invested Capital 204.56M198.66M169.87M194.52M228.54M
Asset Utilization Ratio 0.070.090.510.93
Leverage & Solvency
Interest Coverage Ratio -135.47-50.91-54.50-7.14-40.50-18.23-17.48-4.08
Debt to Equity 1.57
Debt Ratio 0.41
Equity Ratio 0.210.230.220.250.26
Times Interest Earned -135.47-50.91-54.50-7.14-40.50-18.23-17.48-4.08
Valuation
Enterprise Value 1,092.25M741.84M1,956.26M3,454.50M3,426.78M5,164.79M6,741.11M3,556.77M
Market Capitalization 1,092.25M741.84M1,956.26M4,332.15M4,127.33M5,717.86M7,093.41M3,969.38M
Return Ratios
Return on Sales 135.73%50.74%57.66%-1.38%-11.21%-8.65%-1.33%-0.25%
Return on Capital Employed -0.68%-0.91%-0.98%-0.25%
Return on Assets -0.81%-0.79%-0.68%-0.24%
Return on Equity -3.70%-3.54%-2.90%-0.94%